TY - JOUR
T1 - Incident vertebral fractures in children with leukemia during the four years following diagnosis
AU - Cummings, Elizabeth A.
AU - Ma, Jinhui
AU - Fernandez, Conrad V.
AU - Halton, Jacqueline
AU - Alos, Nathalie
AU - Miettunen, Paivi M.
AU - Jaremko, Jacob L.
AU - Ho, Josephine
AU - Shenouda, Nazih
AU - Matzinger, Mary Ann
AU - Lentle, Brian
AU - Stephure, David
AU - Stein, Robert
AU - Sbrocchi, Ann Marie
AU - Rodd, Celia
AU - Lang, Bianca
AU - Israels, Sara
AU - Grant, Ronald M.
AU - Couch, Robert
AU - Barr, Ronald
AU - Hay, John
AU - Rauch, Frank
AU - Siminoski, Kerry
AU - Ward, Leanne M.
N1 - Publisher Copyright:
Copyright © 2015 by the Endocrine Society.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Objectives: The purpose of this article was to determine the incidence and predictors of vertebral fractures (VF) during the 4 years after diagnosis in pediatric acute lymphoblastic leukemia (ALL). Patients and Methods: Children were enrolled within 30 days of chemotherapy initiation, with incident VF assessed annually on lateral spine radiographs according to the Genant method. Extended Cox models were used to assess the association between incident VF and clinical predictors. Results:Atotal of 186 children with ALL completed the baseline evaluation (median age, 5.3 years; interquartile range, 3.4 -9.7 years; 58% boys). The VF incidence rate was 8.7 per 100 person-years, with a 4-year cumulative incidence of 26.4%. The highest annual incidence occurred at 12 months (16.1%; 95% confidence interval [CI], 11.2-22.7), falling to 2.9% at 4 years (95% CI, 1.1-7.3). Half of the children with incident VF had a moderate or severe VF, and 39% of those with incident VF were asymptomatic. Every 10 mg/m2 increase in average daily glucocorticoid dose (prednisone equivalents) was associated with a 5.9-fold increased VF risk (95% CI, 3.0 -11.8; P < .01). Other predictors of increased VF risk included VF at diagnosis, younger age, and lower spine bone mineral density Z-scores at baseline and each annual assessment. Conclusions: One quarter of children with ALL developed incident VF in the 4 years after diagnosis; most of the VF burden was in the first year. Over one third of children with incident VF were asymptomatic. Discrete clinical predictors of a VF were evident early in the patient's clinical course, including a VF at diagnosis.
AB - Objectives: The purpose of this article was to determine the incidence and predictors of vertebral fractures (VF) during the 4 years after diagnosis in pediatric acute lymphoblastic leukemia (ALL). Patients and Methods: Children were enrolled within 30 days of chemotherapy initiation, with incident VF assessed annually on lateral spine radiographs according to the Genant method. Extended Cox models were used to assess the association between incident VF and clinical predictors. Results:Atotal of 186 children with ALL completed the baseline evaluation (median age, 5.3 years; interquartile range, 3.4 -9.7 years; 58% boys). The VF incidence rate was 8.7 per 100 person-years, with a 4-year cumulative incidence of 26.4%. The highest annual incidence occurred at 12 months (16.1%; 95% confidence interval [CI], 11.2-22.7), falling to 2.9% at 4 years (95% CI, 1.1-7.3). Half of the children with incident VF had a moderate or severe VF, and 39% of those with incident VF were asymptomatic. Every 10 mg/m2 increase in average daily glucocorticoid dose (prednisone equivalents) was associated with a 5.9-fold increased VF risk (95% CI, 3.0 -11.8; P < .01). Other predictors of increased VF risk included VF at diagnosis, younger age, and lower spine bone mineral density Z-scores at baseline and each annual assessment. Conclusions: One quarter of children with ALL developed incident VF in the 4 years after diagnosis; most of the VF burden was in the first year. Over one third of children with incident VF were asymptomatic. Discrete clinical predictors of a VF were evident early in the patient's clinical course, including a VF at diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=84941703072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941703072&partnerID=8YFLogxK
U2 - 10.1210/JC.2015-2176
DO - 10.1210/JC.2015-2176
M3 - Article
C2 - 26171800
AN - SCOPUS:84941703072
SN - 0021-972X
VL - 100
SP - 3408
EP - 3417
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 9
ER -